Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA gyrase subunit B (GyrB) is one of the two essential subunits that make up bacterial DNA gyrase, a type II topoisomerase unique to prokaryotes. The enzyme is a heterotetramer composed of two GyrA and two GyrB subunits. DNA gyrase introduces negative supercoils into closed circular double-stranded DNA in an ATP-dependent manner, which is crucial for maintaining the underwound state of bacterial chromosomes and facilitating processes such as replication, transcription, recombination, and repair. GyrB is absent in mammals, making it an attractive target for antibacterial drug development due to its essential role in bacterial viability without off-target effects on human cells. Several antibiotics target either the A or B subunit; novobiocin specifically inhibits the ATP-binding site on GyrB. Recent studies have identified novel small-molecule inhibitors targeting this domain using structure-based virtual screening approaches—these compounds show promising activity against bacterial strains resistant to existing drugs like ciprofloxacin or novobiocin.
Inhibition of ATP binding and hydrolysis; stabilization of specific residues in its active site
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA Gyrase Subunit B (GyrB).